124 related articles for article (PubMed ID: 11340455)
1. [Association between race and incidence of end-stage renal disease secondary to glomerulonephritis: influence of the histologic type and presence of arterial hypertension].
Lopes AA; Silveira MA; Martinelli RP; Rocha H
Rev Assoc Med Bras (1992); 2001; 47(1):78-84. PubMed ID: 11340455
[TBL] [Abstract][Full Text] [Related]
2. [Influence of hypertension on the incidence of end-stage renal disease in negroes and mulattoes with glomerulonephritis].
Lopes AA; Silveira MA; Martinelli R; Noblat AC
Rev Assoc Med Bras (1992); 2002; 48(2):167-71. PubMed ID: 12205536
[TBL] [Abstract][Full Text] [Related]
3. [Racial differences between patients with focal segmental glomerulosclerosis and membranoproliferative glomerulonephritis from the State of Bahia].
Lopes AA; Martinelli RP; Silveira MA; Rocha H
Rev Assoc Med Bras (1992); 1999; 45(2):115-20. PubMed ID: 10413913
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of hypertensive end-stage renal disease: effect of patient's race.
Perneger TV; Whelton PK; Klag MJ; Rossiter KA
Am J Epidemiol; 1995 Jan; 141(1):10-5. PubMed ID: 7801960
[TBL] [Abstract][Full Text] [Related]
5. Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA.
O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Nephrol Dial Transplant; 2016 Feb; 31(2):290-8. PubMed ID: 26610594
[TBL] [Abstract][Full Text] [Related]
6. Association between attributed cause of end-stage renal disease and risk of death in Brazilian patients receiving renal replacement therapy.
Batista PB; Lopes AA; Costa FA
Ren Fail; 2005; 27(6):651-6. PubMed ID: 16350813
[TBL] [Abstract][Full Text] [Related]
7. Renal outcome and risk factors for end-stage renal disease in pediatric rapidly progressive glomerulonephritis.
Piyaphanee N; Ananboontarick C; Supavekin S; Sumboonnanonda A
Pediatr Int; 2017 Mar; 59(3):334-341. PubMed ID: 27542664
[TBL] [Abstract][Full Text] [Related]
8. Incidence of glomerulonephritis and non-diabetic end-stage renal disease in a developing middle-east region near armed conflict.
Ali AA; Sharif DA; Almukhtar SE; Abd KH; Saleem ZSM; Hughson MD
BMC Nephrol; 2018 Oct; 19(1):257. PubMed ID: 30305040
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological profile of patients with end stage renal disease in a referral hospital in Cameroon.
Halle MP; Takongue C; Kengne AP; Kaze FF; Ngu KB
BMC Nephrol; 2015 Apr; 16():59. PubMed ID: 25896605
[TBL] [Abstract][Full Text] [Related]
10. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
[TBL] [Abstract][Full Text] [Related]
11. Report from the Caribbean renal registry, 2006.
Soyibo AK; Barton EN
West Indian Med J; 2007 Sep; 56(4):355-63. PubMed ID: 18198742
[TBL] [Abstract][Full Text] [Related]
12. Incidence of end-stage renal disease in overseas-born, compared with Australian-born, non-indigenous Australians.
Stewart JH; McCredie MR; McDonald SP
Nephrology (Carlton); 2004 Aug; 9(4):247-52. PubMed ID: 15363057
[TBL] [Abstract][Full Text] [Related]
13. Systemic hypertension in patients with glomerulonephritis.
Corpa MV; Soares V
Ren Fail; 2002 May; 24(3):347-52. PubMed ID: 12166701
[TBL] [Abstract][Full Text] [Related]
14. [Systemic arterial hypertension in primary chronic glomerulonephritis: prevalence and its influence on the renal prognosis].
Quirós PL; Ceballos M; Remón C; Hernández Romero MC; Benavides B; Pérez Pérez-Ruilópez MA; Lozano A; Aznar E; Rivero M; Fernández Ruiz E
Nefrologia; 2005; 25(3):250-7. PubMed ID: 16053006
[TBL] [Abstract][Full Text] [Related]
15. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
16. [Hypertension and primary glomerulonephritis in adults. A study of 302 cases].
Seba A; Rayane T; Kaci L; Haddoum F; Benabadji M
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1181-4. PubMed ID: 9404432
[TBL] [Abstract][Full Text] [Related]
17. Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study.
Kwon S; Lee SR; Choi EK; Jung JH; Han KD; Oh S; Lip GYH
Clin Res Cardiol; 2022 Mar; 111(3):284-293. PubMed ID: 34216251
[TBL] [Abstract][Full Text] [Related]
18. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.
Hsu CY; McCulloch CE; Darbinian J; Go AS; Iribarren C
Arch Intern Med; 2005 Apr; 165(8):923-8. PubMed ID: 15851645
[TBL] [Abstract][Full Text] [Related]
19. Patient characteristics and outcomes by GN subtype in ESRD.
O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1170-8. PubMed ID: 26092830
[TBL] [Abstract][Full Text] [Related]
20. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features.
Rosenstock JL; Markowitz GS; Valeri AM; Sacchi G; Appel GB; D'Agati VD
Kidney Int; 2003 Apr; 63(4):1450-61. PubMed ID: 12631361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
